3[3]Yukawa S,Mune M,Yamada Y,et al.Ongoing clinical trials of lipid reduction therapy in patients with renal disease[J].Kidney Int,1999,71 :S141-143.
4[4]Bonnet F,Cooper ME.Potential influence of lipids in diabetic nephropathy:tnsight from experimental data and clinical studies [J].Diabetes Metab,2000,26(4):254-64.
5[5]Robles NR,Ruiz Calero R,Coronado M,et al.Treatment with pravastatin of dyslipidemia associated with diabetic nephropathy[J].An Med Interna,1998,15 (11):572-575.
5Wanner C, Greiber S, Kramer- Guth A, et al. Lipids and progression of renal diseases:role of modified low density lipoprotein nd lipoprotein[J ]. Kidney Int Suppl, 1997, 63: S102-106
6Moorhead J F. Lipids and progressive kidney disease [ J ]. Didney Int Suppl, 1991,31 :s35-40
7Keane WF. The role of lipids in renal desease: future challenges[J]. Kidney Int Suppl,2000,57(75): 14S27-31
8Attman PO,Alaupovic P,Ssmuelsson O. Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease[J ].Kidney Int Suppl, 1999,71: S14-17
9Fogo AB. Progression and potential regression of glomerulosclerosis. Kidney Int ,2001,59(2) :804-819
10Kasiske BL,O'Donnell MP,Schmitz PG,et al. Renal injury of diet- induced hypercholesterolemia in rats [ J ]. Kindey Int,1990,37(3) :880-891
7ZIYADEH F N,SHARMA K. Overview: combating diabetic nephropathy[J]. J Am Soc Nephro, 2003,14(5) : 1355-1357.
8TSUKASA NAKAMURA,YASUHIRO KAWAGOE,TAKESHI SUGAYA, et al. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy[J ]. Diabetes Care, 2005,28 ( 11 ) : 2727-2731.
9ATHYROSV G,PAPAGEORGIOU A A,ELISAF M,et al. Statins and renalfunction in patients with diabetes mellitus [J]. Curr Med Res Op,2003,19(7) :615-617.
10TSUNEKAWA T, HAYASH I T, KANO H,et al. Cerivastatin, a hydroxyl methyl glutaryl coenzyme A reductase inhibitor, imporoves endothelial function in elderly diabetic patents within 3 days[J]. Circulation, 2001,104(4) : 376-379.
